Redirected Immune Cell Therapies
Tuesday, September 14, 2021, 10:30 AM - 5:30 PM EDT
The New York Academy of Sciences
Advances in cancer immunotherapy have demonstrated the critical role T-cells play in mediating anti-cancer effects. Emerging science highlights the expanding repertoire of potentially therapeutic immune cells—for example, macrophages and Natural Killer (NK) cells—as well as the strategies employed for immune cell redirection through innovative format design. While recent clinical advances in T-cell engager (TcE) based treatment of liquid tumors like blinatumomab have heightened expectations for such approaches, multiple questions and challenges remain en route to realizing the full therapeutic potential of redirecting immune cells in the treatment of neoplasms and other diseases.
This symposium will explore basic insights regarding immune-cell trafficking and immunological signaling; multispecific antibody design features enabling optimal biodistribution and activity in target tissues (e.g. solid tumors); and experimental and pharmacokinetic/pharmacodynamic models for more confident clinical translation. It will bring together a cross-disciplinary representation of thought leaders from the immunology, oncology, imaging/microscopy, pharmacometrics and protein engineering fields to not only consider open questions but also propose research toward game-changing breakthroughs.
Call for Abstracts
You are invited to submit a poster abstract to be considered for a virtual poster session and short talks. For submission instructions, please visit our online portal here. The deadline for abstract submission is July 26, 2021.
Memorial Sloan Kettering Cancer Center
Scientific Organizing Committee
New York Academy of Sciences